Monoclonal Gammopathy of Clinical Significance (MGCS) Infosheet
This Infosheet explains what Monoclonal Gammopathy of Clinical Significance (MGCS) is, how it differs from MGUS, and how it is diagnosed and managed. It also covers the condition Monoclonal Gammopathy of Renal Significance (MGRS). This Infosheet covers key questions about MGCS, such as:
- What is MGCS?
- How is MGCS different from MGUS?
- Who can develop MGCS?
- What causes MGCS?
- What are the symptoms of MGCS? – including effects on the kidneys, nerves and skin
- How is MGCS diagnosed?
- How is MGCS treated and monitored?
- Can MGCS develop into other conditions?
- Living well with MGCS
Key points you can read about in this Infosheet include:
- MGCS is a condition where abnormal plasma cells in the bone marrow produce a protein called a paraprotein, and the paraprotein causes specific complications
- MGCS is not a cancer
- MGCS is similar to the related condition MGUS. In MGCS, unlike MGUS, the paraprotein causes symptoms or complications
- The complications are most commonly kidney problems, peripheral neuropathy (a problem with the nerves), or skin symptoms
- In a very small number of cases, MGCS can develop into other conditions, such as myeloma
- Patients with MGCS will be monitored for any change in their condition
- MGCS symptoms and complications are treated as needed
- The underlying abnormal plasma cells will be targeted with specific treatments in some cases
Browse library content
Stay in touch
We’d love to stay in touch. Join our mailing list to receive updates from Myeloma UK including our monthly newsletter and updates about our services, research, campaigns and other ways you can get involved.